ESTIMATION OF SAMARIUM-153 OXABIFORE THERAPY RESULTS OF METASTATIC BONE DISEASE IN COMBINED TREATMENT WITH BISPHOSPHONATES AND IN MONO REGIME BY SEMI-QUANTITATIVE ANALYZE OF WB BONE SCANS
https://doi.org/10.24060/2076-3093-2014-0-1-2-32-38
Abstract
Results of treatment of 54 patients: 43 female with breast cancer and 11 males with prostatic cancer with metastatic bone disease treated with using Sm-153 are assessed. According to semi-quantitative analyze of WB bone scans the most effects results were found in a group of patients who received combined therapy and there where regression of osteoblastic bone metastases in 84,2% of cases, progression is in 7,8%, the same number of patients had simultaneous process: progression and regression. However in patients who were treated with using Sm-153 oxabifore as mono therapy regression of bone metastases was found in 68% of cases, progression is in 25% of the patients and stabilization of metastatic bone disease is in 6,25% of cases.
About the Authors
N. V. Rasulova
Republic Specialized Center of Surgery, Nuclear Medicine Department
Russian Federation
Russian Federation
D. T. Arybzhanov
Russian Federation
V. I. Lyubshin
Russian Federation
R. Karrer
Russian Federation
A. Bartl
Russian Federation
Sz. Wlodarczyk
Russian Federation
V. V. Krylov
Russian Federation
M. Kh. Khodjibekov
Republic Specialized Center of Surgery, Nuclear Medicine Department
Russian Federation
Russian Federation
References
1. Amico S. Liehn J.C. Desoize B., Larbre H, Deltour G., Valeyre J. Comparison of phosphate isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma // Clin Nucl Med. – 1991 - №16. - P 643-648.
2. Badawi JK Radionuclide therapy forthe treatment of skeletal metastases of urological malignancies: a forgotten therapy? // Dtsch Med Wochenschr. – 2012. – Vol. 137. - №33. - P.1645-1649.
3. Bantis A., Grammaticos P. Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate cancer. Can diagnostic significance of PSA be increased? // Hell J Nucl Med. – 2012. - Sep-Dec. - Vol.15. - №3. - P. 241-246.
4. Chybowski F.M., Keller J.L., Bergstralh E.J., Oesterling J.E. Predicting radionuclide bone scan findings in patients with newly diagnosed untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters // J Urol. - 1991. - №145. - P. 313-318.
5. Ferreira S., Dormehl I., Botelho M.F. Radiopharmaceuticals for bone metastasis therapy and beyond: a voyage from the past to the present and a look to the future // Cancer Biother Radiopharm. - 2012. - Vol. 27. - №9. - P. 535-551.
6. Fischer M., Kampen W.U. Radionuclide Therapy of Bone Metastases // Breast Care (Basel). - 2012. – Apr. - Vol. 7. - №2. - P.100-107.
7. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review // Lancet Oncol. - 2005. – Vol. 6. -№6. - P. 392-400.
8. Fizazi K., Bosserman L., Gao G., Skacel T., Markus R. Denosumab Treatment of Prostate Cancer With Bone Metastases and Increased Urine N-Telopeptide Levels After Therapy With Intravenous Bisphosphonates: Results of a Randomized Phase II Trial // J Urol. - 2013. - №189. - 1 Suppl.
9. Jansen D.R., Krijger G.C., Kolar Z.I., Zonnenberg B.A., Zeevaart J.R. Targeted radiotherapy of bone malignancies // Curr Drug Discov Technol. - 2010. - Vol. 7. - №4. - P. 233-246.
10. Liepe K., Kotzerke J. Internal radiotherapy of painful bone metastases // Methods.- 2011. - Vol. 55. - №3. - P. 258-270.
11. Montesano T., Giacomobono S., Acqualagna G. et all. Our experience on pain palliation of bone metastasis with Sr-89 or Sm-153 in cancer patients resistant to a conventional analgesic therapy. A retrospective study //Clin Ter. -2009. - Vol. 160. - №3. - P. 193-199.
12. Ogawa K., Washiyama K.. Bone target radiotracers for palliative therapy of bone metastases // Curr Med Chem. – 2012. - Vol. 19. - №20. - P. 3290- 3300.
13. Sideras P.A., Stavraka A., Gouliamos A., Limouris G.S. Radionuclide Therapy of Painful Bone Metastases--A Comparative Study Between Consecutive Radionuclide Infusions, Combination With Chemotherapy, and Radionuclide Infusions Alone: An In Vivo Comparison of Their Effectiveness. // Am J Hosp Palliat Care. – 2013. - Vol 30. - №8. - P. 745-751.
14. Som A., Tu S.M., Liu J., Wang X., Qiao W., Logothetis C., Corn P.G. Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials // Br J Cancer. – 2012. - Vol. 107. - №9. - P. 1547-1553.
15. Theresa A. Guise, Khalid S.Mohammad,at all. BasicMechanisms Responsible for Osteolytic and Osteoblastic BoneMetastases // Clin Cancer Res. – 2006. - №12. - P. 6213-6216.
16. Tomblyn M. The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases // Cancer Control. – 2012. - Vol. 19. - №2. - P. 137-144.
17. Yusuf E. Erdi,John L.Humm, Massimo Imbriaco, Henry Yeung and Steven M. Larson. Quantitative Bone Mуtastases Analysis Based on Image Segmentation. // J Nucl. Med. – 1997. - № 38. - P. 1401-1406.
18. ZhaoW.W.,Xie P.,DengH.F. Strontium-89 for bone metastases from prostate cancer: an update // Zhonghua Nan Ke Xue. – 2010. - Vol. – 16. - № 3. - P. 269-272.
Review
For citations:
Rasulova N.V., Arybzhanov D.T., Lyubshin V.I., Karrer R., Bartl A., Wlodarczyk S., Krylov V.V., Khodjibekov M.Kh. ESTIMATION OF SAMARIUM-153 OXABIFORE THERAPY RESULTS OF METASTATIC BONE DISEASE IN COMBINED TREATMENT WITH BISPHOSPHONATES AND IN MONO REGIME BY SEMI-QUANTITATIVE ANALYZE OF WB BONE SCANS. Creative surgery and oncology. 2014;(1-2):32-38. (In Russ.) https://doi.org/10.24060/2076-3093-2014-0-1-2-32-38
Views:
2788
Email this article 